You should make an updated Mounjaro video. I was recently put on it for my type-2 diabetes (totally missed all the "buzz" surrounding it) but TBH, I get tired of watching "personal experience vlogs" about weight-loss and would appreciate a "latest facts & findings" video with updated content in your typical format of delivery.
@VernCrisler Жыл бұрын
Good discussion. So, heart rate increased for the first 6 months, then subsided. If I were obese, I would think that obesity is a greater danger than a temporary increase in my heart rate. Since I'm on Mounjaro for A1c purposes, retatrutide (too many t's) doesn't really appeal as much as Mounjaro. More significantly, the increased GI effects might make it less tolerable for both diabetic and obesity patients. Gees, how many gut hormones do we have? And why haven't researchers tried to invoke all of them at once to achieve synergistic effects?
@winterfavorite62609 ай бұрын
I did not lose weight with Mounjaro 5mg. Next week i will be using 7.5 hopefully it will work. No side effect but no weight loss.
@westvillefinest6972 ай бұрын
I've lost 31lbs so far on retatrutide so far on it, it so amazing on taking away appetite and hungry
@erica931428 күн бұрын
What about side effects?
@tehillanaiman94512 күн бұрын
It's only coming out on 2026...
@westvillefinest69712 күн бұрын
@@tehillanaiman945 I have it all ready
@westvillefinest69712 күн бұрын
@@erica9314 if there any atleast all be skinny
@westvillefinest6975 күн бұрын
@@tehillanaiman945 ok that why I take it twice a week huh
@LoganDavid7 ай бұрын
The most concise and clear comparison of the big 3 I've found so far. With the most optimal case of release date being sometime in 2026, those who need this type of therapy shouldn't wait for it, IMO. Consider the "bang for the buck" with Mounjaro, and Wegovy to benefit weight loss while we wait for Reta to release.
@lrblouie9 ай бұрын
Excellent presentation; thank you for keeping it easy to understand! :)
@kevinsutube1p5283 ай бұрын
Alright, that seals it. Gonna order some. Just gonna do a low dose for 4 or 5 weeks and see how it goes
@Metarig2 ай бұрын
You gotta wait til next year to get your hands on it
@kevinsutube1p5282 ай бұрын
@@Metarig nope. easy to get
@knkootbaoat6759 Жыл бұрын
in terms of the weight loss % what's the breakdown between muscle loss % vs fat loss %
@VernCrisler Жыл бұрын
Most is fat loss, but resistance exercise is still recommended for any diet.
@knkootbaoat6759 Жыл бұрын
@@VernCrisler thanks. +1 the resistance training
@jeanroc101011 ай бұрын
Awesome
@HMinot4 ай бұрын
I’ve been invited to participate in a study, with free retatrutide for five years. But those side effects…
@RoxannaKlineАй бұрын
Do you have a diluting & dosingg chart
@belleairBabe8 ай бұрын
So what better ?
@UltimoDogLover Жыл бұрын
Actually, wegovy and mounjaro both increase heartrate too. And it's right in their labels.
@cloakster Жыл бұрын
Yes, but if you look at the retatrutide trial data, 6 percent of all participants had heart arrhythmia issues. Don’t know the severity, but still… very concerning. 😯
@UltimoDogLover Жыл бұрын
@@cloakster Yes, I'd have to look back at the trials for the others to compare, so it may be more significant with retatrutide. Nonetheless, all GLP-1 agonists act on the autonomic nervous system and significantly increase mean daily heart rates. And can increase likelihood of arrythmias.
@cloakster Жыл бұрын
@Brooks Looking it up… In the Tirzepatide trial I found, there was no results line for ‘heart arrhythmia’. There IS a line for ‘cardiac disorders’ though… overall rate was 0.2 percent, aka about 30 times lower than the cardiac arrhythmia rate in the retatrutide study. Also, both studies have a ‘major adverse cardiovascular effects’ results line. In the Tirzepatide study, the rate was less than 0.5 percent overall. In the Retatrutide study, it was 1 percent. Draw your own conclusions, but I hope the final Phase 3 trials resolve this, one way or the other. 🤔
@UltimoDogLover Жыл бұрын
@@cloakster I doubt they are going to "resolve" it. It's just not going to be suitable for everyone. Like stimulant based fat loss drugs phenteramine and fenfluramine. Drugs have side effects. The question is whether they are significant enough or common enough to negate approval.
@cloakster Жыл бұрын
@Brooks From Lilly’s point of view, I think they kind of have to ‘resolve’ it, or at least mitigate it, because their FDA approval is on the line. A 6 percent overall cardiac arrhythmia rate is legit cause for concern, and at the highest two doses, it was much worse… 14 percent and 11 percent, respectively. 😯 Not only that, but even if retatrutide is somehow able to be approved with those arrhythmia rates (and there are OTHER issues too, such as nausea and vomiting at the highest doses at 2x to 3x the rate of high-dose Tirzepatide)… many ppl just WON’T WANT to take a drug with that kind of side effects profile. 😬 There’d also be VERY significant bad word-of-mouth on social media, plus a great many panicky media articles and stories. ‘Set up to fail?’ Yeah, kind of. 📰 So yeah, they do have to at least mitigate it. The GOOD news is that much of the problem seems to be dose-dependent. Eliminate the top two doses, and the arrhythmia rate drops to 4 percent. And the nausea and vomiting rates drop to about high-dose Tirzepatide levels. Combine that with a slow/gentle upward titration schedule, and they may be just fine. The only drawback is that with the elimination of the highest doses, they’d be giving up some (but not all) of its weight-loss advantage over Mounjaro and Wegovy. But, it’s almost certainly worth it. 🤔 My 2.0 cents… YMMV.
@stevengower7 ай бұрын
Glucagon receptors seem to be an issue with heart arythmias
@bwilsonduncan7 ай бұрын
Same question as I have with the other weight loss drugs: what about maintenance? Do I have to take it forever? Is there a treatment plan for reduced dosage for maintenance?
@bwilsonduncan7 ай бұрын
In fact, I think it's a bit irresponsible to launch a product without it being paired with a follow-up maintenance plan.
@billyhw54922 ай бұрын
Yes, you have to take it forever, just like you would have to take blood pressure medication forever. If you stop taking it you gain all the weight back.
@kiabias8 ай бұрын
So if I have access to retatrutide right now and have low blood pressure in general, is it safe for me to try it for 7 weeks?
@jimjohngirard10 ай бұрын
Retatrutide is still in clinical trials....any idea when this agonist will be approved by the FDA and introduced and also, will it be efficacious for type 2 diabetes?
@anke5088 Жыл бұрын
liraglutide raises Resting HR as well
@sunscrave8 ай бұрын
Don't sema and terza also increase HR?
@bertimus7031 Жыл бұрын
How can we get retatrutide, trial or otherwise?
@cloakster Жыл бұрын
Right now, only in the clinical trials.
@cloakster9 ай бұрын
ps - There’s also compounding pharmacy and grey-market ‘research-grade’ (read: for use in animals) reta out there… but the risks are significant, both health-wise and in terms of getting ripped off.
@CaseyKCRichards6 ай бұрын
They al give heart issues… but you didnt talk about wegovy or Tirzapatide with heart issues.. you slammed Retatrutide.
@jimlastname5152 Жыл бұрын
Considering the Phase 3 retatrutide trial TRIUMPH-3 for subjects with CVD requires a BMI >=35, I wouldn't be concerned about 6 months of increasing heart rate especially considering many subjects might lose 25-50 lbs during that period. IAC, I still have 4.5 years in the SURMOUNT-MMO trial for subjects with CVD so I'm more concerned about my increase in heart rate on Mounjaro. Concerned enough that I may decide to see my cardiologist.
@hbshearin Жыл бұрын
Please do not introduce as though there are only a few, if you are truly a GI physician; you must know and tell there are many that have been around for along time.
@cloakster Жыл бұрын
Yes, but there’s only a few (so far) that deliver really major weight-loss. It’s not for nothing that Ozempic and Wegovy were/are called ‘game-changers’.